Upgrade to SI Premium - Free Trial

Akebia Therapeutics (AKBA)

0.96 +0.01 (1.05%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

Akebia doses first patient in Phase 2 kidney disease trial September 14, 2026 8:02 AM - StreetInsider Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases September 14, 2026 8:00 AM - Globe NewsWire WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy September 8, 2026 8:40 AM - StreetInsider Form 4 Akebia Therapeutics, For: Aug 06 Filed by: Butler John P. August 10, 2026 4:09 PM - SEC Filing Leerink Downgrades Akebia Therapeutics (AKBA) to Market Perform August 7, 2026 6:11 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA) August 6, 2026 6:58 AM - StreetInsider Akebia Therapeutics (AKBA) Tops Q2 EPS by 1c August 5, 2026 5:10 PM - StreetInsider Form S-8 Akebia Therapeutics, August 5, 2026 4:58 PM - SEC Filing Form 10-Q Akebia Therapeutics, For: Jun 30 August 5, 2026 4:15 PM - SEC Filing Form 8-K Akebia Therapeutics, For: Aug 05 August 5, 2026 4:13 PM - SEC Filing Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights August 5, 2026 4:06 PM - Globe NewsWire Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 3, 2026 4:05 PM - Globe NewsWire Akebia starts Phase 2 trial for rare kidney disease drug ebribafusp August 3, 2026 8:00 AM - StreetInsider Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases August 3, 2026 8:00 AM - Globe NewsWire Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights July 29, 2026 8:00 AM - Globe NewsWire Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 2, 2026 4:05 PM - Globe NewsWire Form 4 Akebia Therapeutics, For: Jun 29 Filed by: Ostrowski Erik July 1, 2026 4:34 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA) July 1, 2026 7:03 AM - StreetInsider Form 8-K Akebia Therapeutics, For: Jun 30 June 30, 2026 8:05 AM - SEC Filing Vafseo trial stopped early after interim data shows fewer hospitalizations June 30, 2026 8:02 AM - StreetInsider U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA June 30, 2026 8:01 AM - Globe NewsWire Form 144 Akebia Therapeutics, Filed by: Ostrowski Erik June 29, 2026 8:38 PM - SEC Filing Form 4 Akebia Therapeutics, For: Jun 17 Filed by: Wolf Myles June 22, 2026 4:25 PM - SEC Filing Form 4 Akebia Therapeutics, For: Jun 17 Filed by: Smith Cynthia June 22, 2026 4:24 PM - SEC Filing Form 4 Akebia Therapeutics, For: Jun 17 Filed by: ROGERS MICHAEL W June 22, 2026 4:22 PM - SEC Filing Form 4 Akebia Therapeutics, For: Jun 17 Filed by: FRIESON RON June 22, 2026 4:20 PM - SEC Filing Form 8-K Akebia Therapeutics, For: Jun 17 June 22, 2026 4:17 PM - SEC Filing Form 4 Akebia Therapeutics, For: Jun 17 Filed by: ZUMWALT LEANNE M June 22, 2026 4:11 PM - SEC Filing Form 4 Akebia Therapeutics, For: Jun 17 Filed by: ADAMS ADRIAN June 22, 2026 4:09 PM - SEC Filing Full Article List